

For pediatric and AYA patients with high-risk B-cell precursor ALL in first relapse

# BLINCYTO<sup>®</sup>—because his dreams are bigger than ALL


A targeted immunotherapy powered by BiTE<sup>®</sup> technology, BLINCYTO<sup>®</sup> offers a chemo-minimizing approach that significantly improves survival and offers fewer and less severe toxicities versus additional chemotherapy.<sup>1,2</sup>



ALL, acute lymphoblastic leukemia; AYA, adolescent and young adult; BiTE, Bispecific T-cell Engager.

**References:** 1. Locatelli F, Zugmaier G, Rizzari C, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. *JAMA*. 2021;325:843-854. 2. Brown PA, Ji L, Xu X, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. *JAMA*. 2021;325:833-842.

BLINCYTO<sup>®</sup> is a registered trademark of Amgen Inc.  
© 2021 Amgen Inc. All rights reserved.

 **BLINCYTO<sup>®</sup>**  
(blinatumomab) infusion




PR-BLI-GULF-000017-09-2021

GU-103-1222-80001

For pediatric and AYA patients with high-risk B-cell precursor ALL in first relapse

# BLINCYTO<sup>®</sup>—because her dreams are bigger than ALL

A targeted immunotherapy powered by BiTE<sup>®</sup> technology, BLINCYTO<sup>®</sup> offers a chemo-minimizing approach that significantly improves survival and offers fewer and less severe toxicities versus additional chemotherapy.<sup>1,2</sup>



PR-BLI-GULF-000017-09-2021

ALL, acute lymphoblastic leukemia; AYA, adolescent and young adult; BiTE, Bispecific T-cell Engager.

**References:** 1. Locatelli F, Zugmaier G, Rizzari C, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. *JAMA*. 2021;325:843-854. 2. Brown PA, Ji L, Xu X, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. *JAMA*. 2021;325:833-842.

BLINCYTO<sup>®</sup> is a registered trademark of Amgen Inc. © 2021 Amgen Inc. All rights reserved.

GU-103-1222-80001



 **BLINCYTO<sup>®</sup>**  
(blinatumomab) infusion





API available Upon Request



For pediatric and AYA patients with high-risk B-cell precursor ALL in first relapse

# BLINCYTO<sup>®</sup>—because her dreams are bigger than ALL

A targeted immunotherapy powered by BiTE<sup>®</sup> technology, BLINCYTO<sup>®</sup> offers a chemo-minimizing approach that significantly improves survival and offers fewer and less severe toxicities versus additional chemotherapy.



PR-BLI-GULF-000017-09-2021

ALL, acute lymphoblastic leukemia; AYA, adolescent and young adult; BiTE, Bispecific T-cell Engager.

**Reference:** Brown PA, Ji L, Xu X, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. *JAMA*. 2021;325:833-842.

BLINCYTO<sup>®</sup> is a registered trademark of Amgen Inc.  
© 2021 Amgen Inc. All rights reserved.



GU-103-1222-80001

API available Upon Request

## Age group 5-11

For pediatric and AYA patients with high-risk B-cell precursor ALL in first relapse

### BLINCYTO®—because his dreams are bigger than ALL

A targeted immunotherapy powered by BiTE® technology, BLINCYTO® offers a chemo-minimizing approach that significantly improves survival and offers fewer and less severe toxicities versus additional chemotherapy.<sup>1,2</sup>



ALL, acute lymphoblastic leukemia; AYA, adolescent and young adult; BiTE, Bispecific T-cell Engager.

References: 1. Locatelli F, Zugmaier G, Rizzari C, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:843-854. 2. Brown PA, Ji L, Xu X, et al. Effect of postremission therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:833-842.

BLINCYTO® is a registered trademark of Amgen Inc. © 2021 Amgen Inc. All rights reserved.

**BLINCYTO**  
(blinatumomab) infusion

## Age group 12-18

For pediatric and AYA patients with high-risk B-cell precursor ALL in first relapse

### BLINCYTO®—because her dreams are bigger than ALL

A targeted immunotherapy powered by BiTE® technology, BLINCYTO® offers a chemo-minimizing approach that significantly improves survival and offers fewer and less severe toxicities versus additional chemotherapy.<sup>1,2</sup>



ALL, acute lymphoblastic leukemia; AYA, adolescent and young adult; BiTE, Bispecific T-cell Engager.

References: 1. Locatelli F, Zugmaier G, Rizzari C, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:843-854. 2. Brown PA, Ji L, Xu X, et al. Effect of postremission therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:833-842.

BLINCYTO® is a registered trademark of Amgen Inc. © 2021 Amgen Inc. All rights reserved.


**BLINCYTO**  
(blinatumomab) infusion

## Age group 19-30

For pediatric and AYA patients with high-risk B-cell precursor ALL in first relapse

### BLINCYTO®—because her dreams are bigger than ALL

A targeted immunotherapy powered by BiTE® technology, BLINCYTO® offers a chemo-minimizing approach that significantly improves survival and offers fewer and less severe toxicities versus additional chemotherapy.



ALL, acute lymphoblastic leukemia; AYA, adolescent and young adult; BiTE, Bispecific T-cell Engager.

References: Brown PA, Ji L, Xu X, et al. Effect of postremission therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:833-842.

BLINCYTO® is a registered trademark of Amgen Inc. © 2021 Amgen Inc. All rights reserved.

**BLINCYTO**  
(blinatumomab) infusion